ADMA Biologics, Inc. ADMA
ADMA Biologics, Inc. (Nasdaq: ADMA) is an infectious disease drug developer. Its lead program, SG-001, is in Pre-clinical for Treatment and prevention of S. pneumoniae infection. Its next catalyst on record is SG-001: IND submission (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: SG-001 — IND submission (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SG-001 | Treatment and prevention of S. pneumoniae infection | protein/peptide | Pre-clinical |
Recent results and decisions
- May 4, 2026approval FDA approved ADMA's sBLA expanding the ASCENIV label to pediatric PI patients aged 2 years and older (previously 12+).
Additionally, the approval provides for a revision of ASCENIV’s prescribing information to expand the primary humoral immunodeficiency (“PI”) indication to pediatric patients two years of age and older.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.